Loading
A phase 1/2 trial of Lutetium-177 dotatate, FAP-2286, Atezolizumab in small-cell lung cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab is a phase 1/2 interventional study registered as NCT05142696 by Novartis Pharmaceuticals, with 55 participants enrolled, started 2022-07-13 and due to reach its primary completion in 2028-03-07. Interventions recorded: [177Lu]Lu-DOTA-TATE, Atezolizumab, [68Ga]Ga-DOTA-TATE, Carboplatin, Etoposide. Conditions listed: Extensive Stage Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Novartis, Small-cell lung cancer.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Immune checkpoint inhibitors.
Shares Extensive-stage small-cell lung cancer, Atezolizumab, Small-cell lung cancer, Immune checkpoint inhibitors.